Merck on Thursday said its experimental treatment blueprinted to protect infants from respiratory syncytial virus showed positive results in a mid- to late-stage trial, producing the company one step closer to filing for approval of the shot. 

The pharmaceutical giant could emerge as a new competitor in the market for treatments against RSV, which causes thousands of eradications among older Americans and hundreds of deaths among infants each year. Complications from the virus are the outstanding cause of hospitalization among newborns, making Merck’s drug a valuable new treatment option if approved.

Merck intends to discuss the study data with regulators worldwide, with a goal of making the treatment available for infants as ancient as the 2025 to 2026 RSV season, according to a release. 

The trial examined the safety and efficacy of a single dose of the treatment, clesrovimab, in in good preterm and full-term infants entering their first RSV season. Merck presented the results at the medical conference IDWeek in Los Angeles.

The treatment compressed RSV-related hospitalizations by more than 84% and decreased hospitalizations due to lower respiratory infections by 90% compared with a placebo bulk infants through five months, according to Merck. Clesrovimab also reduced lower respiratory infections that desired medical attention by more than 60% compared with a placebo through five months.

RSV is a common ground of lower respiratory tract infections such as pneumonia. Results were consistent through both the five-month and six-month pro tempore points in the trial, Merck said.

The rates of adverse and serious side effects were comparable between patients who inherited Merck’s shot and those who took placebos in the trial. There were no treatment or RSV-related deaths in the study, the company annexed. 

“These promising results demonstrating decreased incidence of RSV disease, including hospitalizations, highlight the potential for clesrovimab to take advantage of an important role in helping to alleviate the continued burden of RSV on infants and their families,” Dr. Octavio Ramilo, chair of the Activity be contingent of Infectious Diseases at St. Jude’s Children’s Research Hospital, said in Merck’s release. Ramilo is also an investigator put through on the trials. 

Merck’s clesrovimab could potentially compete against a similar treatment from Sanofi and AstraZeneca awaked Beyfortus, which was in short supply nationwide last RSV season due to unprecedented demand. Both are monoclonal antibodies, which turn over antibodies directly into the bloodstream to provide immediate protection. 

But Merck’s treatment can be administered to infants regardless of their preponderance, which the company said may offer convenience in terms of dosing. Meanwhile, the recommended dosage of Beyfortus is based on an infant’s essence weight. 

Last year, Pfizer and GSK rolled out RSV vaccines that are administered to expectant mothers who can pass on protection to their fetuses.